Search Results - lymphoma

9 Results

Sort By:

Optimized Monospecific or Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20

Abstract: Patients with chemotherapy-refractory, diffuse large B-cell lymphoma (DLBCL) have poor prognoses. CD19 and CD20 are promising targets for the treatment of B-Cell malignancies. However, despite the initial promising results from anti-CD19 CAR therapy, only 30-35% of patients with DLBCL achieve remissions lasting longer than 2-3 years after...

Published: 8/14/2024 | Inventor(s): James Kochenderfer, Norris Lam

Keywords(s): act, adoptive cell therapy, Autoimmune, B Cell Malignancies, BICISTRONIC, CAR, CD19, CD20, chimeric antigen receptor, Kochenderfer, Leukemia, lymphoma, Monospecific

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Oncology

Bicistronic Chimeric Antigen Receptor (CAR) Constructs Targeting CD19 and CD20

Abstract: CD19 and CD20 are promising targets for the treatment of B-Cell malignancies. Unfortunately, some clinical studies have shown that there is a loss of CD19 or CD20 expression in various cases of lymphomas and leukemias, particularly after treatment with an agent that targets CD19 (e.g., anti-CD19 CAR-T). However, studies have shown that expression...

Published: 8/14/2024 | Inventor(s): James Kochenderfer, Shicheng Yang

Keywords(s): act, adoptive cell therapy, B Cell Malignancies, BICISTRONIC, CAR, CD19, CD20, chimeric antigen receptor, Kochenderfer, Leukemia, lymphoma

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

A Target for the Development of Diagnostics and Therapeutics for Abnormal Hematopoiesis

The zinc finger protein ZFP36L2 has been shown by the inventors to play an essential role in hematopoiesis, a process that is dysregulated in hematological cancers, anemia, and other conditions. Thus, ZFP36L2 has promise for use in a diagnostic test to detect abnormal hematopoiesis, or as a target for the development of therapeutics to treat abnormal...

Published: 4/8/2024 | Inventor(s): Deborah Stumpo, Perry Blackshear

Keywords(s): (4)r syndrome, anemia, Blood, C syndrome, CANCER, Chromosome 4 ring syndrome, Chromosome 6 ring syndrome, Chromosome 7 ring syndrome, Chronic myelogenous leukemia, diagnostic, Diagnostic assay, diagnostic test, G syndrome, Hematologic, Hematopoiesis, Hypertelorism with esophageal abnormality and hypospadias, IAXXXX, IBXXXX, IXXXXX, Leukemia, lymphoma, N syndrome, Patent Category - Biotechnology, R(6) syndrome, R(7) syndrome, Syndrome X, therapeutic, Thrombocytopenia 2, Thrombocytopenia chromosome breakage, Tristetraprolin, W syndrome, W syndrome; Syndrome W, ZFP36L2, zinc finger

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Diagnostics, Application > Research Materials, Application > Therapeutics

Eeyarestatins: Novel Deubiquitination Inhibitors for the Treatment of Drug-Resistant Cancers

The ubiquitin-proteasome system has recently been recognized to play a central role in tumor biology. Bortezomib, an inhibitor of the chymotrypsin-like activity of the proteasome, has clinical activity in a variety of hematologic malignancies and is FDA approved for use in Multiple Myeloma and Mantle Cell Lymphoma. The present invention for the first...

Published: 7/25/2024 | Inventor(s): Helena Mora-Jensen, Qiuyan Wang, Yihong Ye, Adrian Wiestner

Keywords(s): Active, Against, BBXXXX, Bortezomib, CANCER, CB5EXX, CB5XXX, CBXXXX, Cells, Chronic lymphocytic leukemia, COMPOSITION, CXXXXX, DB4AXX, DB4XXX, DBXXXX, Deubiquination, DXXXXX, Eeyarestatin, Hematologic, Highly, HIV AIDS - Therapeutics, Including, inhibitor, lymphoma, Mantle cell lymphoma, MULTIPLE MYELOMA, Proteasome, RESISTANT, That, tumor

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Oncology

Methods for Prevention and Treatment of Polyomavirus Infection or Reactivation (E-179-2007)

Available for licensing and commercial development are methods of using Tranilast [N-(3',4'-dimethoxycinnamoyl)anthranilic acid] in the prevention and treatment of human polyomavirus infection. Treatment with Tranilast decreases viral protein expression for two human polyomavirus species, JC virus (JCV) and BK virus (BKV). Furthermore, the increase...

Published: 4/8/2024 | Inventor(s): Jeffrey Kopp, Eugene Major, Veerasamy Ravichandran

Keywords(s): BBXXXX, BK, BKV, DB4XXX, DBXXXX, DXXXXX, HIV AIDS, IMMUNOCOMPROMISED, Infection, inhibitor, JC, JCV, leukoencephalopathy, lymphoma, nephrophathy, PML, polyomavirus, Polyomavirus Infections, Polyomaviruses, Progressive multifocal leukoencephalopathy, TGF-B, Tranilast, virus

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics

Methods for Expression and Purification of Immunotoxins

The invention concerns immunotoxins and methods of making the immunotoxins. Targeting of the immunotoxins occurs via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the immune system by accentuating tolerizing responses. As...

Published: 7/25/2024 | Inventor(s): David Neville

Keywords(s): Aplastic anemia, Are, Bivalent, CB6XXX, CBXXXX, COMPLEX, CXXXXX, ESSENTIAL, Graft versus host disease, IB3XXX, IBXXXX, Immunotoxin, IXXXXX, LOW, lymphoma, Media, PASTORIS, PICHIA, production, temperature

Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Immunology, Application > Diagnostics, Application > Therapeutics, TherapeuticArea > Oncology

Immunotoxin with in-vivo T cell Suppressant Activity

The invention concerns immunotoxins and methods of using the immunotoxins for the treatment of autoimmune diseases and T cell malignancies. The immunotoxins are targeted via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the...

Published: 7/25/2024 | Inventor(s): David Neville

Keywords(s): Activity, Aplastic anemia, CB1XXX, CBXXXX, Cell, CXXXXX, IB3XXX, IBXXXX, IMMUNE, Immunotoxin, IMMUNOTOXINS, INDUCING, IN-VIVO, IXXXXX, lymphoma, Methods, Novel, SUPPRESSANT, T, TOLERANCE, UAXXXX, Vivo

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Immunology, TherapeuticArea > Rare / Neglected Diseases, Application > Diagnostics, Application > Research Materials, Application > Therapeutics

Methods for Prevention and Treatment of Polyomavirus Infection or Reactivation

Available for licensing and commercial development are methods of using two MAP kinase kinase (MEK) inhibitors, PD98059 and U0126, in the prevention and treatment of polyomavirus infection. Decrease in viral protein expression upon treatment with the MEK inhibitors has been demonstrated for two polyomavirus species, JC virus (JCV) and BK virus (BKV)....

Published: 4/8/2024 | Inventor(s): Eugene Major, Veerasamy Ravichandran

Keywords(s): BBXXXX, BK, BKV, DB4BXX, DB4XXX, DBXXXX, DXXXXX, EFFECTOR, Idenitification, Infection, Infections;, inhibitor, Inhibitors, JC, JCV, lymphoma, MAP-kinase-, MEK, PD98059, Polyomavirus Infections, Progressive multifocal leukoencephalopathy, U0126, virus

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics

Selections of Genes

The invention provides selections of genes expressed in a cancer cell that function to characterize such cancer, and methods of using the same for diagnosis and for targeting the therapy of selected cancers. In particular, methods are provided to classify cancers belonging to distinct diagnostic categories, which often present diagnostic dilemmas in...

Published: 7/25/2024 | Inventor(s): Javed Khan, Paul Meltzer

Keywords(s): AAXXXX, AXXXXX, Burkitt lymphoma; Burkitt's lymphoma, Burkitt's lymphoma, CA1AXX, CAXXXX, CXXXXX, Ewing's family of tumors, lymphoma, Neuroblastoma, Rhabdomyosarcoma 1, Rhabdomyosarcoma 2

Category(s): Collaboration Sought > Licensing, Application > Diagnostics, TherapeuticArea > Oncology